PharmiWeb.com - Global Pharma News & Resources
09-Apr-2021

Pharyngitis Therapeutics Market 2021 Trends, Size Analysis, Share, Leading Companies, Future Insights and Top Manufacturers, Forecast To 2027

SEATTLE, April 09, 2021, (PHARMIWEB) — Global Pharyngitis Therapeutics Market

Pharyngitis, commonly referred to as sore throat, causes inflammation of the pharynx located behind the throat. The condition is generally caused by bacterial or viral infections, and pharyngitis cases are majorly observed during the colder months of the year. Measles, adenovirus, chickenpox, croup, whooping cough, and group A streptococcus are the major causes of pharyngitis. Pharyngitis is also commonly caused by viral infections, such as common cold, influenza, and mononucleosis. According to the Centers for Disease Control and Prevention (CDC), amoxicillin and penicillin are the most commonly prescribed therapeutics for sore throat.

*The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2001

Pharyngitis treatment is majorly based on the symptoms, depending upon the cause of pharyngitis, for example, bacterial, fungal, and herpes simplex infections. The common symptoms of pharyngitis include sneezing, runny nose, headache, cough, fatigue, body aches, chills, and fever. Furthermore, the condition is mostly followed by a strep throat, which may lead to difficulty in swallowing, loss of appetite, nausea, fever, loss of taste, and swollen lymph nodes. Pain medications, such as NSAIDs and acetaminophen, are usually recommended for reduction in pain associated with pharyngitis. Also, aspirin is used by adults, which is however, not recommended for children due to the risk of the Reye syndrome occurrence.

Furthermore, steroids such as dexamethasone are also useful for treating pharyngitis. If the infection is caused by bacteria, then these steroids are taken with antibiotics, however, if caused by virus, antibiotics shows no positive results. Moreover, oral analgesic solutions are also prescribed with active ingredient phenol as a medication for pharyngitis. A wide range of options available for the treatment of pharyngitis, in turn, supports the growth of the global pharyngitis therapeutics market.

Global Pharyngitis Therapeutics Market Dynamics

According to a study published by the CDC and Pew Charitable Trusts in 2016, doctors are often prescribing the wrong antibiotics, which concluded that only 52% of the 44 million antibiotic prescribed for sinus infections, middle ear infections, and pharyngitis are the first-line drugs. Furthermore, in 2017, the World Health Organization (WHO) released a report suggesting that there is a serious lack of new antibiotics in development, underscoring that antibiotic resistance is a global health emergency set to undermine the decades of progress in modern medicine.

Therefore, manufactures are increasingly focusing on research and development for new discovery of antibiotics or any other therapeutic drugs to aid in pharyngitis treatment. For instance, Innovative Med Concepts, Inc. is in the process of developing a promising treatment for pharyngitis, i.e. the company’s second novel product NRP-1 (a proprietary throat spray), is designed to treat viral pharyngitis, which is expected to cater to the unmet medical needs and causes of most cases of pharyngitis. NRP-1 will also provide the required relief for cancer patients undergoing head and neck radiation plagued with disabling oral mucositis/pharyngitis. This spray delivers medication, which then adheres to the posterior pharynx despite repeated swallows and saliva.

Global Pharyngitis Therapeutics Market – Regional Insights

North America, followed by Europe, accounted for the largest share in the global pharyngitis therapeutics market in 2016. This is attributed to increasing prevalence of pharyngitis in North America. According to data published in American Family Physician Journal in 2009, pharyngitis is diagnosed in 11 million people in outpatient settings, each year in the U.S.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding in the Asia Pacific region, to maximize their R&D efforts, as the region provides a low-capital investment in research and development due to lower operational costs and highly efficient technicians. Increasing government investment in research and development is also expected to foster growth of the pharyngitis therapeutics market in Asia Pacific. As Group A Streptococcus is the most common disease caused in settings of poverty, where transmission of an organism is possible due to the poor living conditions. Hence, the Asia Pacific region provides innumerable prospects for drug manufacturers around the world.

Global Pharyngitis Therapeutics Market – Competitive Analysis

The major players operating in the global pharyngitis therapeutics market include Genentech Inc., Adamas Pharmaceutical Inc., PLIVA HRVATSKA d.o.o., Pfizer Inc., Valeant Pharmaceuticals International, Inc., Mylan N.V., GSK group of companies, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2001

Market Taxonomy

By Source of Infection:

  • Viral
  • Bacterial

By Drug Class:

  • Antiviral Drugs
  • Antibacterial Drugs
  • Anti-inflammatory Drugs
  • Topical Anesthetics Drugs

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 09-Apr-2021